smpc semaglutide Switching between weight-loss medications Two-year effects of semaglutide in

As a precaution, retatrutide would likely carry the same class-level thyroid warnings as other GLP-1 medications, and it would not be recommended for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

There is evidence here

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide carry the clinical evidence: STEP for semaglutide ( The New England Journal of Medicine , 2021), SURMOUNT for tirzepatide (NEJM, 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM, 2024)

This lets you focus entirely on your science